Leadiant Biosciences controversies
Controversies tied to this brand in public sources. A listing is not a finding of fault.
Back to profile1 entries
2018
Chenodeoxycholic acid pricing controversy
Leadiant Biosciences was criticized after the price of chenodeoxycholic acid reportedly rose from a low per-capsule price to approximately EUR 140 per capsule. Patient advocates and competition-policy commentators argued that the company had exploited a dominant position involving an orphan medicine, making treatment unaffordable for some patients with cerebrotendinous xanthomatosis.